ARVO 2024: Detection of glaucoma with a novel widefield imaging device combined with OCT

At this year's ARVO meeting, Michael Chaglasian, OD, spoke with Ophthalmology Times about the paper he presented on the detection of glaucoma with a novel widefield imaging device combined with OCT.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Michael Chaglasian, OD:

Hi, Mike Chaglasian, Illinois College of Optometry, Illinois Eye Institute, where I'm associate professor and chief of staff. Here at the ARVO meeting in Seattle, where my poster was, "Detection of glaucoma with a novel widefield imaging device combined with OCT."

So in this poster, we looked at a group of glaucoma individuals along with a group of normal individuals, and use the Optos Monaco device. This is a new device in the past few years that combines traditional ultra widefield fundus imaging along with spectral domain OCT.

And in our study, we looked at 33 glaucoma subjects with a wide range of glaucoma severity, along with a matched age group of normal individuals. And we use the Monaco device to identify the detection of glaucoma as compared to the normal individuals. So we looked at the area under the ROC curves for sensitivities in the detection of glaucoma disease in our groups. So, what we found for the results, for this small study, was that the strongest indicators of detecting glaucoma based on optic disk size was vertical CD ratio and rim area. They had ROCs is of 0.98 and 0.96. Also, average retinal nerve fiber layer thickness (RNFL) and inferior RNFL thickness were also very strong indicators of glaucoma disease. And then finally, in the last scan set was glaucoma ganglion cell complex, and this had a very strong indicator for average GCC values for detection of glaucoma. So in conclusion, this small study looked at a new device, the Monaco OCT combined with ultra widefield imaging from Optos, and we identified that it had a strong and positive ability to detect glaucoma as compared to normal individuals.

And so the goal of this project was to identify this new and novel device is on par with our currently available technologies on OCT imaging to detect glaucoma at approximately the same rate as is reported in the literature. So practicing optometrists and ophthalmologists can feel confident that the Monaco OCT is going to do that glaucoma detection for them. Yeah, and the next step certainly would be to expand our subject size, since we had a small group here of just 33 individuals with glaucoma and 33 age-match normals. We will want to expand this to a larger database. My financial disclosure is that I do research work with Optos.